An opioid-dependence treatment being developed by BioDelivery Sciences International (NASDAQ:BDSI) is on track for a New Drug Application filing in the second half of 2012, making it a contender to compete against current market leader Reckitt Benckiser (LSE:RB). Raleigh, North Carolina-based specialty pharmaceutical company BDSI announced positive preliminary results from a clinical trial that studied […]
BioDelivery Sciences International‘s (NASDAQ:BDSI) treatment for breakthrough cancer pain is now slated to launch in Canada this quarter – more than a year after the company had initially planned its Canada launch. Raleigh, North Carolina-based BDSI received Health Canada approval for Onsolis in May 2010, which put the product on a track for a Canada […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tough. It’s even tougher when direct competitors don’t have those same limits. That’s the situation facing Raleigh, North Carolina-based BioDelivery Sciences International (NASDAQ:BDSI). A cancer patient seeking relief from breakthrough cancer pain would be able to fill a prescription […]
North Carolina pharmaceutical company BioDelivery Sciences International has extended its patent in Canada by 10 years, giving additional protection for the company’s core drug delivery technology. Raleigh, North Carolina based BDSI’s (NASDAQ:BDSI) drug delivery technology releases medicine to a patient via a small piece of dissolvable film placed on the inside of the cheek. BDSI […]
BioDelivery Sciences International, a Raleigh, North Carolina, company whose lead product delivers a pain-killing cancer drug, says that a patent infringement lawsuit filed by New Jersey-based MonoSol Rx has no merit.